unresectable advanced pancreatic cancer
Conditions
Interventions
Irinotecan is administered with 90 min intravenous infusion on day 1,15 every 4 weeks. L-OHP is administered with 120 min intravenous infusion on day 1,15 every 4 weeks. S-1 is taken orally on day
Sponsors
the university of tokushima
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)unresectable invasive or reccurence advanced pancraatic carcinoma (2)first line treatment (3)Patients must be >=20 years old and <=80 years old (4)ECOG Performance Status must be 0 or 1. (5)The following criteria must be satisfied in laboratory tests. 1) Hemoglobin >= 9.0 g/dL 2) White blood cell count >=3,000/mm3 ,Neutrophil count >=1,500/mm3 3)Platelet count >=75,000mm3 4)Total bilirubin <=one and a half times as many as average level baseline 5)AST,ALT,ALP<= two and a half times as many as average level baseline 6) Serum Creatinine <=average level baseline (6)Life expectancy > 90 days. (7)Patients or legal representative must have signed the consent form.
Exclusion criteria
Exclusion criteria: (1) infusion of blood products within 7days (2) not first line treatment (3) severe Allergie (4) much ascites or pleural effusion (5) infection (6) diarrea (7) ileus (8) neuropathy (9) severe heart disorder (10) neuropsychiatric disorder (11) idiopathic pulmonary fibrosis or Idiopathic interstitial pneumonia (12) brain metastasis (13) pregnancy case (14) unsuitable case
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTD and DLT and RD | — |
Countries
Japan
Contacts
Public Contacttakayama tetsuji
the university of tokushima department of gastroenterology
Outcome results
None listed